Enobosarm, also formerly known as ostarine and by the developmental code names GTx-024 and MK-2866, is a selective androgen receptor modulator (SARM) which is under development for the treatment of breast cancer. It was also under development for a variety of other indications, including treatment of cachexia, Duchenne muscular dystrophy, muscular atrophy, and stress incontinence, but development for all other uses has been discontinued.